Northern Ontario School of Medicine University, Sudbury, Ontario, Canada.
Health Sciences North, Sudbury, Ontario, Canada.
BMJ Open. 2024 Feb 24;14(2):e080790. doi: 10.1136/bmjopen-2023-080790.
The Canadian Addiction Treatment Centre (CATC) cohort was established during a period of increased provision of opioid agonist treatment (OAT), to study patient outcomes and trends related to the treatment of opioid use disorder (OUD) in Canada. The CATC cohort's strengths lie in its unique physician network, shared care model and event-level data, making it valuable for validation and integration studies. The CATC cohort is a valuable resource for examining OAT outcomes, providing insights into substance use trends and the impact of service-level factors.
The CATC cohort comprises 32 246 people who received OAT prescriptions between April 2014 and February 2021, with ongoing tri-annual updates planned until 2027. The cohort includes data from all CATC clinics' electronic medical records and includes demographic information and OAT clinical indicators.
This cohort profile describes the demographic and clinical characteristics of patients being treated in a large OAT physician network. As well, we report the longitudinal OAT retention by treatment type during a time of increasing exposure to a contaminated dangerous drug supply. Notable findings also include retention differences between methadone (32% of patients at 1 year) and buprenorphine (20% at 1 year). Previously published research from this cohort indicated that patient-level factors associated with retention include geographic location, concurrent substance use and prior treatment attempts. Service-level factors such as telemedicine delivery and frequency of urine drug screenings also influence retention. Additionally, the cohort identified rising OAT participation and a substantial increase in fentanyl use during the COVID-19 pandemic.
Future research objectives are the longitudinal evaluation of retention and flexible modelling techniques that account for the changes as patients are treated with OAT. Furthermore, future research aims are the use of conditional models, and linkage with provincial-level administrative datasets.
加拿大成瘾治疗中心 (CATC) 队列是在阿片类激动剂治疗 (OAT) 增加供应期间建立的,旨在研究与加拿大阿片类药物使用障碍 (OUD) 治疗相关的患者结局和趋势。CATC 队列的优势在于其独特的医生网络、共同护理模式和事件级别的数据,使其成为验证和整合研究的有价值资源。CATC 队列是研究 OAT 结局的宝贵资源,为了解物质使用趋势和服务水平因素的影响提供了深入了解。
CATC 队列包括 32246 人,他们在 2014 年 4 月至 2021 年 2 月期间接受了 OAT 处方,计划在 2027 年前每三年进行一次更新。该队列包含来自所有 CATC 诊所电子病历的数据,包括人口统计学信息和 OAT 临床指标。
本队列概况描述了在大型 OAT 医生网络中接受治疗的患者的人口统计学和临床特征。此外,我们报告了在接触受污染的危险药物供应增加期间,按治疗类型划分的纵向 OAT 保留情况。值得注意的发现还包括美沙酮(1 年内 32%的患者)和丁丙诺啡(1 年内 20%的患者)之间的保留差异。来自该队列的先前发表的研究表明,与保留相关的患者因素包括地理位置、同时使用其他物质和之前的治疗尝试。服务水平因素,如远程医疗的提供和尿液药物筛查的频率,也会影响保留率。此外,该队列还发现 OAT 参与人数增加和 COVID-19 大流行期间芬太尼使用大幅增加。
未来的研究目标是对保留率进行纵向评估,并使用灵活的建模技术来考虑随着患者接受 OAT 治疗而发生的变化。此外,未来的研究目标是使用条件模型,并与省级行政数据集进行链接。